I know that it is only one of the secondary endpointA, but I’m most interested to see what the viral load does in the M/M trial. When the Remdesivir trial came out that resulted in emergency approval, there was a lot of pushback from the medical community since it was an antiviral that didn’t actually reduce viral levels. If Leronlimab brings viral load down to zero or near-zero, that is something that even the least scientific American can understand. Less virus is more better, right?
News 
Market Data 
Discover 
AI
